Literature DB >> 20102109

Advances in imaging low-grade gliomas.

Stephen J Price1.   

Abstract

Imaging plays a key role in the management of low-grade gliomas. The traditional view of these tumours as non-enhancing areas of increased signal on T2-weighted imaging is now accepted as being incorrect. Using new MR and PET techniques that can probe the pathological changes with in these tumours by assessing vascularity (perfusion MR), cellularity and infiltration (diffusion weighted and diffusion tensor MR), metabolism (MR spectroscopy and FDG PET) and proliferation (MR spectroscopy, methionine PET and 18F-fluorothymidine FLT PET). These tools will allow improvements in tumour grading, biopsy/therapy guidance and earlier assessment of the response to therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20102109     DOI: 10.1007/978-3-211-99481-8_1

Source DB:  PubMed          Journal:  Adv Tech Stand Neurosurg        ISSN: 0095-4829


  16 in total

1.  Fast spectroscopic multiple analysis (FASMA) for brain tumor classification: a clinical decision support system utilizing multi-parametric 3T MR data.

Authors:  Evangelia Tsolaki; Patricia Svolos; Evanthia Kousi; Eftychia Kapsalaki; Ioannis Fezoulidis; Konstantinos Fountas; Kyriaki Theodorou; Constantine Kappas; Ioannis Tsougos
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-07-15       Impact factor: 2.924

2.  Potential role for magnetoencephalography in distinguishing low- and high-grade gliomas: a preliminary study with histopathological confirmation.

Authors:  Tony W Wilson; Elizabeth Heinrichs-Graham; Michele R Aizenberg
Journal:  Neuro Oncol       Date:  2012-03-23       Impact factor: 12.300

3.  Correlation between cerebral blood volume measurements by perfusion-weighted magnetic resonance imaging and two-year progression-free survival in gliomas.

Authors:  M V Spampinato; C Schiarelli; A Cianfoni; P Giglio; C T Welsh; S Bisdas; Z Rumboldt
Journal:  Neuroradiol J       Date:  2013-08-27

4.  Prediction of malignancy grading using computed tomography perfusion imaging in nonenhancing supratentorial gliomas.

Authors:  Takaaki Beppu; Makoto Sasaki; Kohsuke Kudo; Akira Kurose; Masaru Takeda; Hiroshi Kashimura; Akira Ogawa; Kuniaki Ogasawara
Journal:  J Neurooncol       Date:  2010-10-15       Impact factor: 4.130

5.  Quantitative characterization of the imaging limits of diffuse low-grade oligodendrogliomas.

Authors:  Chloé Gerin; Johan Pallud; Christophe Deroulers; Pascale Varlet; Catherine Oppenheim; Francois-Xavier Roux; Fabrice Chrétien; Stephen R Thomas; Basile Grammaticos; Mathilde Badoual
Journal:  Neuro Oncol       Date:  2013-06-14       Impact factor: 12.300

6.  Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.

Authors:  Chris E Adkins; Afroz S Mohammad; Tori B Terrell-Hall; Emma L Dolan; Neal Shah; Emily Sechrest; Jessica Griffith; Paul R Lockman
Journal:  Clin Exp Metastasis       Date:  2016-03-05       Impact factor: 5.150

7.  Oedema-based model for diffuse low-grade gliomas: application to clinical cases under radiotherapy.

Authors:  M Badoual; C Gerin; C Deroulers; B Grammaticos; J-F Llitjos; C Oppenheim; P Varlet; J Pallud
Journal:  Cell Prolif       Date:  2014-06-19       Impact factor: 6.831

8.  Resting state fMRI feature-based cerebral glioma grading by support vector machine.

Authors:  Jiangfen Wu; Zhiyu Qian; Ling Tao; Jianhua Yin; Shangwen Ding; Yameng Zhang; Zhou Yu
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-09-17       Impact factor: 2.924

9.  Advanced neuroimaging in the clinic: critical appraisal of the evidence base.

Authors:  Adam Z Fink; Lisa B Mogil; Michael L Lipton
Journal:  Br J Radiol       Date:  2016-05-05       Impact factor: 3.039

Review 10.  The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.